source
- FDA delays decision on Savara's rare lung disease therapy, pushing back deadlineThe FDA announced it will not meet the Nov. 22 PDUFA date for Savara's biologics license application for its inhaled therapy molgramostim (Molbreevi) targeting autoimmune pulmonary alveolar protein…
- Celldex halts eczema development of barzolvolimab after Phase 2 miss, eyes chronic hives filingCelldex Therapeutics announced it will stop developing its lead antibody barzolvolimab for eczema after the Phase 2 trial did not meet its internal efficacy threshold. The company said it will sti…